Skip to content
10-Q

Quarterly Report

REGENERX BIOPHARMACEUTICALS, INC.

0001410578-23-001223

← back to feed
Filed
May 15, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 11, 2023 143.55M sh
Shares Diluted Q1 2023 · Mar 31, 2023 143.55M sh
Shares Diluted Q1 2023 · Mar 31, 2022 143.55M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$189.33K
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$306.3K
Cash And Equivalents Q1 2023 · Mar 31, 2023 $101.56K
Cash And Equivalents Q1 2023 · Dec 31, 2022 $290.89K
Stockholders Equity Q1 2023 · Mar 31, 2023 −$3.74M
Stockholders Equity Q1 2023 · Dec 31, 2022 −$3.45M
Stockholders Equity Q1 2023 · Mar 31, 2022 −$2.57M
Stockholders Equity Q1 2023 · Dec 31, 2021 −$2.23M
Current Liabilities Q1 2023 · Mar 31, 2023 $1.8M
Current Liabilities Q1 2023 · Dec 31, 2022 $553.67K
Total Liabilities Q1 2023 · Mar 31, 2023 $3.93M
Total Liabilities Q1 2023 · Dec 31, 2022 $3.83M
Current Assets Q1 2023 · Mar 31, 2023 $123.26K
Current Assets Q1 2023 · Dec 31, 2022 $306.92K
Total Assets Q1 2023 · Mar 31, 2023 $186.81K
Total Assets Q1 2023 · Dec 31, 2022 $382.18K
Eps Diluted Q1 2023 · Mar 31, 2023 $0.00
Eps Diluted Q1 2023 · Mar 31, 2022 $0.00
Eps Basic Q1 2023 · Mar 31, 2023 $0.00
Eps Basic Q1 2023 · Mar 31, 2022 $0.00
Sga Expense Q1 2023 · Mar 31, 2023 $324.1K
Sga Expense Q1 2023 · Mar 31, 2022 $363.03K
Net Income Q1 2023 · Mar 31, 2023 −$385.2K
Net Income Q1 2023 · Mar 31, 2022 −$424.07K
Operating Income Q1 2023 · Mar 31, 2023 −$304.91K
Operating Income Q1 2023 · Mar 31, 2022 −$343.84K
Revenue Q1 2023 · Mar 31, 2023 $19.19K
Revenue Q1 2023 · Mar 31, 2022 $19.19K